Schedule 13D ownership disclosure

EDESA BIOTECH INC

Common Shares, without par value · CUSIP: 27966L306

Event date: 2026-02-26

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Velan Capital Master Fund LPReported CIK 0001964356

    Shares: 569,075.00 · Class: 6.8%

  • Velan Horizon Fund LPReported CIK 0002057740

    Shares: 15,625.00 · Class: 0.2%

  • Velan Capital Opportunity Fund II LLCReported CIK 0002057744

    Shares: 250,000.00 · Class: 3.0%

  • Velan Horizon GP LLCReported CIK 0002057821

    Shares: 15,625.00 · Class: 0.2%

  • Velan Capital Holdings LLCReported CIK 0001964353

    Shares: 819,075.00 · Class: 9.8%

  • Velan Capital Investment Management LPReported CIK 0001848809

    Shares: 834,700.00 · Class: 9.99%

  • Velan Capital Management LLCReported CIK 0001964355

    Shares: 834,700.00 · Class: 9.99%

  • Morgan AdamReported CIK 0001964335

    Shares: 834,700.00 · Class: 9.99%

  • VENKATARAMAN BALAJIReported CIK 0001114916

    Shares: 834,700.00 · Class: 9.99%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000921895-26-000578
Form type
SCHEDULE 13D/A
Filer
Edesa Biotech, Inc.
CIK
CIK 1540159
Filed
Mar 02, 2026
Reporting period
Feb 26, 2026
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub